Richard Chen
Equibles does not estimate personal net worth.
Get an email with a short summary when Personalis, Inc. publishes a filing, an earnings call transcript or a press release.
Get PSNL alertsAbout Richard Chen
Personalis, Inc. reported in an 8-K filed March 17, 2026 that Richard Chen was appointed President, effective March 13, 2026. Personalis, Inc. reported in an 8-K filed March 8, 2023 that Richard Chen was appointed Executive Vice President, R&D, effective March 2, 2023. The proxy statement of Personalis, Inc. reports total compensation of $1,589,150 for Richard Chen in fiscal 2025, including a base salary of $530,450. Disclosed compensation is on record for 8 fiscal years. Personalis, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Personalis, Inc. includes Aaron Tachibana (CEO, CFO and COO), Christopher Hall (CEO and Board Member), Christopher M. Hall (CEO and Board Member) and 7 others.
“On March 13, 2026, the board of directors (the “Board”) of Personalis, Inc. (the “Company”), based in part on the recommendation of Christopher Hall, the Company’s Chief Executive Officer, appointed Richard Chen as the Company’s President, in addition to his roles as the Company’s Executive Vice President, R&D, and Chief Medical Officer.”
“(iii) Richard Chen as the Company's Executive Vice President, R&D, promoted from Vice President, R&D, in addition to his role as Chief Medical Officer.”
Affiliation history
-
Personalis, Inc. (PSNL)
Proxy statement
CurrentStart not stated–present
Last confirmed April 2, 2026
Company network
Leadership on record at Personalis, Inc.
- Aaron Tachibana CEO, CFO, COO
- Christopher Hall CEO, Board Member
- Christopher M. Hall CEO, Board Member
- Karin Eastham Chairman
- Aaron L. Tachibana CFO
- Stephen Moore General Counsel
- Kenneth Widder Board Member
- Olivia K. Bloom Board Member
- Woodrow (Woody) A. Myers, Jr., M.D. Board Member
- Woodrow A. Myers Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Personalis, Inc. (PSNL) | M.D., M.S. President, Executive Vice President, Research and Development and Chief Medical Officer | $530,450 | $1,589,150 |
| 2024 | Personalis, Inc. (PSNL) | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $511,250 | $989,394 |
| 2023 | Personalis, Inc. (PSNL) | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $498,500 | $1,277,500 |
| 2022 | Personalis, Inc. (PSNL) | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $489,250 | $690,576 |
| 2021 | Personalis, Inc. (PSNL) | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $468,750 | $3,056,713 |
| 2020 | Personalis, Inc. (PSNL) | M.D., M.S. Chief Scientific Officer | $437,500 | $1,436,461 |
| 2019 | Personalis, Inc. (PSNL) | M.D., M.S. Chief Scientific Officer | $393,751 | $632,351 |
| 2018 | Personalis, Inc. (PSNL) | M.D., M.S. Chief Scientific Officer | $370,031 | $840,965 |